Literature DB >> 26037942

Inhibition of BRAF and MEK in BRAF-mutant melanoma.

Keiran S M Smalley1, Vernon K Sondak2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26037942     DOI： 10.1016/S0140-6736(15)60972-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway.

Authors:  Xiangjun Chen; Hao Dong; Sha Liu; Li Yu; Dexiong Yan; Xingwei Yao; Weijing Sun; Dezhi Han; Guozhen Gao
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

2.  Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.

Authors:  Dinoop Ravindran Menon; Helmut Schaider
Journal:  J Invest Dermatol       Date:  2015-12       Impact factor: 8.551

Review 3.  Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.

Authors:  Mengdong Liu; Xuekang Yang; Jiaqi Liu; Bin Zhao; Weixia Cai; Yan Li; Dahai Hu
Journal:  Oncotarget       Date:  2017-05-09

4.  Long Noncoding RNA PVT1 as a Novel Diagnostic Biomarker and Therapeutic Target for Melanoma.

Authors:  Xiangjun Chen; Guozhen Gao; Sha Liu; Li Yu; Dexiong Yan; Xingwei Yao; Weijing Sun; Dezhi Han; Hao Dong
Journal:  Biomed Res Int       Date:  2017-02-07       Impact factor: 3.411

5.  Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.

Authors:  Shumin Yuan; Qiang Fu; Lingdi Zhao; Xiaomin Fu; Tiepeng Li; Lu Han; Peng Qin; Yingkun Ren; Mingke Huo; Zhimeng Li; Chaomin Lu; Long Yuan; Quanli Gao; Zibing Wang
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837

6.  Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis.

Authors:  Ye Liu; Xilan Zhang; Guoying Wang; Xinchang Cui
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.